GOLDMAN SACHS GROUP INC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$8,853,092
-24.4%
195,045
-6.4%
0.00%
-33.3%
Q2 2023$11,704,348
-16.1%
208,485
-32.4%
0.00%0.0%
Q1 2023$13,951,374
-48.3%
308,454
-53.5%
0.00%
-57.1%
Q4 2022$26,988,876
-61.6%
663,933
-38.2%
0.01%
-56.2%
Q3 2022$70,212,000
+80.9%
1,074,406
+68.2%
0.02%
+77.8%
Q2 2022$38,814,000
+430.3%
638,706
+447.8%
0.01%
+350.0%
Q1 2022$7,319,000
-58.8%
116,597
-50.2%
0.00%
-33.3%
Q4 2021$17,746,000
-51.7%
234,186
-28.6%
0.00%
-62.5%
Q3 2021$36,722,000
+195.8%
328,082
+327.9%
0.01%
+166.7%
Q2 2021$12,414,000
-10.3%
76,681
-32.5%
0.00%0.0%
Q1 2021$13,838,000
-27.8%
113,573
-9.3%
0.00%
-40.0%
Q4 2020$19,168,000
+197.9%
125,190
+62.7%
0.01%
+150.0%
Q3 2020$6,434,000
-20.5%
76,927
-30.1%
0.00%0.0%
Q2 2020$8,088,000
+82.7%
110,058
+5.4%
0.00%0.0%
Q1 2020$4,428,000
-55.7%
104,401
-36.4%
0.00%0.0%
Q4 2019$10,005,000
+335.6%
164,262
+193.2%
0.00%
+100.0%
Q3 2019$2,297,000
-4.1%
56,028
+10.2%
0.00%0.0%
Q2 2019$2,396,000
+61.8%
50,853
+22.6%
0.00%
Q1 2019$1,481,000
+0.3%
41,465
-19.8%
0.00%
Q4 2018$1,476,000
-34.3%
51,679
+2.0%
0.00%
-100.0%
Q3 2018$2,246,000
-28.7%
50,650
-5.5%
0.00%0.0%
Q2 2018$3,148,000
+149.8%
53,578
+94.4%
0.00%
Q1 2018$1,260,000
+136.8%
27,562
+21.6%
0.00%
Q4 2017$532,00022,6720.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders